Response Genetics Gets $8.8 Million in Private Placement

Los Angeles-based Response Genetics, a publicly held provider of molecular diagnostic testing services for cancer, announced this morning that it has raised $8.8M in a private placement of its stock. The new funding came from GlaxoSmithKline and an un-named, existing stockholder. GlaxoSmithKline is a new investor in the company. Response Genetics said the new funding will go towards "buiolding a sustainable business" and grow its top line revenue. More information »